Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05061537 · OUTCOME

Part 2: Progression Free Survival

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors · Source last updated 2024-04-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From start date of treatment to the date of first documentation of PD or death due to any cause (up to 2 years)

What was measured

Progression free survival was defined as time from start date of treatment to the date of first documentation of PD or death due to any cause. PD was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm and unequivocal progression of pre-existing lesions.

Analysis population: Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.

Groups in this outcome

Part 2: PF-07263689 + Sasanlimab

Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 2: PF-07263689 + Sasanlimab0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Progression free survival was defined as time from start date of treatment to the date of first documentation of PD or death due to any cause. PD was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm and unequivocal progression of pre-existing lesions.
groups
  1. description
    Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.
    id
    OG000
    title
    Part 2: PF-07263689 + Sasanlimab
population Description
Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.
reporting Status
POSTED
time Frame
From start date of treatment to the date of first documentation of PD or death due to any cause (up to 2 years)
title
Part 2: Progression Free Survival
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice